Human CTLA-4 antibodies and their uses
The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
1. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR3 domains are selected from the group consisting of:
(a) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:37; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:35; and
(b) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:38; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:36;
and binds to human CTLA-4 with a binding affinity of about 10 8 M −1 or greater.
2. A method for treating cancer in a subject, the method comprising administering to the subject an antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof
competes for binding to a human CTLA-4 polypeptide with a reference antibody comprising the amino acid sequence set forth in SEQ ID NO: 17, and the amino acid sequence set forth in SEQ ID NO: 7; and
has a binding affinity of about 10 8 M −1 or greater.
3. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises:
(a) a heavy chain variable region derived from a human V H 3-30.3 gene; and
(b) a light chain variable region derived from a human V K A-27 gene.
4. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises:
(a) a heavy chain variable region derived from a human V H 3-33 gene; and
(b) a light chain variable region derived from a human V K L-15 gene.
5. The method of claim 1 , wherein the antibody inhibits binding of human CTLA-4 to B7-1 and B7-2.
6. The method of claim 1 or 2 , wherein the antibody is a human antibody.
7. The method of claim 1 or 2 , wherein the antibody is a monoclonal antibody.
8. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises at least one heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17, 19 and 23.
9. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises at least one light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9 and 13.
10. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7.
11. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9.
12. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13.
13. The method of claim 3 , wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 37, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 35.
14. The method of claim 4 , wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 38, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 36.
15. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 32 and 37, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 24, 29 and 35, respectively.
16. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 33 and 37, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 25, 30 and 35, respectively.
17. The method of claim 1 , wherein the antibody or antigen-binding portion thereof comprises:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 28, 34 and 38, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 26, 31 and 36, respectively.
18. The method of claim 1 or 2 , wherein the cancer is selected from the group consisting of melanoma and prostate cancer.
19. The method of claim 1 or 2 , wherein the method further comprises administering a vaccine.
20. The method of claim 19 , wherein the vaccine is selected from the group consisting of a tumor cell vaccine, a GM-CSF-modified tumor cell vaccine, an IL-2-modified tumor cell vaccine, an antigen-loaded dentritic cell vaccine, and a TRAMP tumor cell vaccine.
21. The method of claim 1 or 2 , wherein the method further comprises administering an antigen.
22. The method of claim 21 , wherein the antigen is a tumor antigen.
23. The method of claim 22 , wherein the tumor antigen is selected from the group consisting of a prostate tumor antigen, a melanoma tumor antigen, and an epithelial tumor antigen.
24. The method of claim 21 , wherein the antigen is selected from the group consisting of gp 100, MAGE, Trp-2, telomerase, and heat shock protein (HSP).
25. The method of claim 1 or 2 , wherein the method further comprises administering a chemotherapeutic agent.
26. The method of claim 1 , wherein the heavy chain variable region and light chain variable region CDR2 domains are selected from the group consisting of
(a) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:32; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:29;
(b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:33; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:30; and
(c) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:34; and a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:31.
27. The method of claim 1 or 26 , wherein the heavy chain variable region and light chain variable region CDR1 domains are selected from the group consisting of:
(a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:27; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:24;
(b) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:27; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:25; and
(c) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:28; and a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:26.
28. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 32 and 37, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 24, 29 and 35, respectively.
29. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 33 and 37, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 25, 30 and 35, respectively.
30. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, comprising:
(a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 28, 34 and 38, respectively; and
(b) a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 26, 31 and 36, respectively.
31. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7.
32. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9.
33. A method for treating cancer in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13.